Implications of liraglutide in diabetic patients

Authors

DOI:

https://doi.org/10.33448/rsd-v13i8.46569

Keywords:

Liraglutide; Diabetes Mellitus; Drug therapy.

Abstract

Diabetes Mellitus (DM) is a multifactorial disease, including peripheral resistance, associated with higher rates of hospitalizations, incidence of cardiovascular and cerebrovascular diseases, blindness, renal failure and non-traumatic amputations. It is estimated that the global affected population is expected to reach 471 million in 2035. The objective of this article is to present a bibliographic review study that seeks to elucidate the therapeutic use of liraglutide in the treatment of DM, considering mechanisms of action in the physiology of the disease and discussing the physiological impacts of the use of liraglutide on the body. This is a narrative review in the PUBMED and SciELO databases of systematic reviews and meta-analyses from 2010 to 2024, using the keywords: “Liraglutide”; “Diabetes Mellitus”; “Drug Therapy”, with free full text that addresses the topic sought. Liraglutide is an incretinomimetic drug, which increases insulin secretion by pancreatic beta cells, decreases glucagon secretion, delays gastric emptying and decreases appetite. In addition to glycemic control, liraglutide has a significant effect on reducing body weight. The long-term safety of liraglutide in association with neoplasms is reported to be rare and continues to be studied. It appears, therefore, that GLP-1 analogues have a multifaceted role in the treatment of DM2. Despite optimism, new studies are awaited to rule out unfavorable implications for human health.

References

Arderius, M., Santos, R. A., Silva, F. M., & Pereira, J. A. (2016). Liraglutido: Avaliação do benefício clínico numa população portuguesa com diabetes de difícil controlo. Medicina Interna, 23(4), 16-21.

Astrup, A., Carraro, R., Finer, N., et al. (2021). Liraglutide 3.0 mg for the treatment of obesity: A randomized, double-blind, placebo-controlled trial. The Lancet, 398(10298), 695-707. https://doi.org/10.1016/S0140-6736(21)01458-7

Baggio, L. L., & Drucker, D. J. (2022). Glucagon-like peptide-1 and glucose homeostasis. Physiological Reviews, 102(4), 1593-1653. https://doi.org/10.1152/physrev.00019.2021

Bica, I. C., Pietroșel, V. A., Salmen, T., Diaconu, C. T., Fierbinteanu Braticevici, C., Stoica, R. A., Suceveanu, A. I., & Pantea Stoian, A. (2023). The effects of cardioprotective antidiabetic therapy on microbiota in patients with type 2 diabetes mellitus: A systematic review. International Journal of Molecular Sciences, 24(8), 7184. https://doi.org/10.3390/ijms24087184

Cruz, D. S. M. da, Oliveira, M. C., & Almeida, C. L. (2017). Vivências de mães de crianças diabéticas. Escola Anna Nery, 21(1), 1-9. https://doi.org/10.5935/1414-8145.20170001

Faria, A. M., Oliveira, C. R., & Pinto, J. C. (2010). Progressos recentes e novas perspectivas em farmacoterapia da obesidade. Arquivos Brasileiros de Endocrinologia e Metabologia, 54(6), 516-529. https://doi.org/10.1590/S0004-27302010000600009

Garber, A. J., Henry, R. R., Horton, E. S., et al. (2020). Liraglutide versus placebo or metformin monotherapy in patients with type 2 diabetes: A meta-analysis. Diabetologia, 63(1), 116-128. https://doi.org/10.1007/s00125-019-05016-x

García-Casares, N., González-González, G., de la Cruz-Cosme, C., Garzón-Maldonado, F. J., de Rojas-Leal, C., Ariza, M. J., Narváez, M., Barbancho, M. Á., García-Arnés, J. A., & Tinahones, F. J. (2023). Effects of GLP-1 receptor agonists on neurological complications of diabetes. Reviews in Endocrine and Metabolic Disorders, 24(4), 655-672. https://doi.org/10.1007/s11154-023-09807-3

Hu, E. H., Tsai, M. L., Lin, Y., Chou, T. S., & Chen, T. H. (2024). A review and meta-analysis of the safety and efficacy of using glucagon-like peptide-1 receptor agonists. Medicina (Kaunas), 60(3), 357. https://doi.org/10.3390/medicina60030357

Kristensen, S. L., Rørth, R., Jhund, P. S., et al. (2022). Effect of liraglutide on cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis of 8 trials. The Lancet Diabetes & Endocrinology, 10(7), 468-479. https://doi.org/10.1016/S2213-8587(22)00089-2

Loke, Y. K., Kwok, C. S., Singh, S., et al. (2020). Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism, 105(1), 202-214. https://doi.org/10.1210/jc.2019-01188

Macêdo, S. F., Silva, A. M., & Costa, C. A. (2010). Fatores de risco para diabetes mellitus tipo 2 em crianças. Revista Latino-Americana de Enfermagem, 18(5), 935-941. https://doi.org/10.1590/S0104-11692010000500009

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2019). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322. https://doi.org/10.1056/NEJMoa1603827

Nauck, M. A., Quast, D. R., Wefers, J., & Gallwitz, B. (2019). GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Molecular Metabolism, 30, 72-130. https://doi.org/10.1016/j.molmet.2019.08.003

Nauck, M. A., Quast, D. R., Wefers, J., & Gutzwiller, J. P. (2020). The role of GLP-1 receptor agonists in the management of type 2 diabetes: Current evidence and future perspectives. Diabetes Therapy, 11(2), 227-240. https://doi.org/10.1007/s13300-019-00777-x

Okido, A. C. C., Pereira, A. G., & Ramos, L. B. (2017). As demandas de cuidado das crianças com Diabetes Mellitus tipo 1. Escola Anna Nery, 21(2), 235-242. https://doi.org/10.5935/1414-8145.20170030

Sousa, A. S.; Oliveira, G. S.; Alves, L. H (2021). A pesquisa bibliográfica: princípios e fundamentos. Cadernos da Fucamp, 20(43).

Sigwalt, F. R., Silva, R. C. R. D., & Santos, D. R. (2014). Resistência à insulina em adolescentes com e sem excesso de peso de município da Grande Florianópolis-SC. Revista Brasileira de Enfermagem, 67(1), 43-47. https://doi.org/10.5935/0034-7167.20140008

Sociedade Brasileira de Diabetes (SBD). (2014). Diretrizes do diabetes mellitus jovem. Arquivos Brasileiros de Cardiologia, 95(1), 1-51. https://doi.org/10.5935/abc.20140049

Venancio, J. P., La Banca, R. O., & Ribeiro, C. A. (2017). Benefícios da participação em um acampamento no autocuidado de crianças e adolescentes com diabetes: Percepção das mães. Escola Anna Nery, 21(1), 1-8. https://doi.org/10.5935/1414-8145.20170009

Veronese, A., Silva, R. M., & Ribeiro, J. M. (2015). Instrumentos para avaliação da qualidade de vida em crianças e adolescentes com diabetes mellitus. Revista e Clínica de Enfermagem, 19(3), 768-773. https://doi.org/10.5935/1415-2762.20150017

Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023). Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: A systematic review. Frontiers in Endocrinology (Lausanne), 14, 1244432. https://doi.org/10.3389/fendo.2023.1244432

Downloads

Published

23/08/2024

How to Cite

MELO FILHO, C. G.; FIGUEREDO, P. de C. .; MARINHO, L. B. .; MARTINS, A. L. F. R. .; FREIRE, R. C. .; FERREIRA , R. S. A. .; ULISSES, J. R. R. M. .; BRITTO, M. L. T. D. .; SILVA, G. C. da .; FREITAS, G. A. .; JANSEN, V. M. C. . Implications of liraglutide in diabetic patients. Research, Society and Development, [S. l.], v. 13, n. 8, p. e8913846569, 2024. DOI: 10.33448/rsd-v13i8.46569. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/46569. Acesso em: 6 sep. 2024.

Issue

Vol. 13 No. 8

Section

Health Sciences

License

Copyright (c) 2024 Carlos Gonzaga Melo Filho; Pedro de Carvalho Figueredo; Letícia Batalha Marinho; Ana Luiza Fernandes Raposo Martins; Renata Correia Freire; Rafael Sousa Araújo Ferreira ; João Rafael Raposo Martins Ulisses; Maria Luiza Tenório Dantas Britto; Gisele Chaves da Silva; Gabriela Alencar Freitas; Vânia Maria Carvalho Jansen

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.